

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JOINN LABORATORIES (CHINA) CO., LTD.

北京昭衍新藥研究中心股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6127)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the announcement issued by JOINN Laboratories (China) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on 30 August 2024 in relation to the continuing connected transactions contemplated in the 2024 Beijing JOINN Biologics Leasing Framework Agreement and the BioAI Service Framework Agreement (the “**Announcement**”). Unless otherwise specified in this announcement, terms used herein shall have the same meanings as those defined in the Announcement. The Company wishes to provide further information in relation to the Announcement as follows:

Previous transactions conducted under the 2023 Beijing JOINN Biologics Leasing Agreement and the 2024 BioAI Software Service Framework Agreement

The total rent paid under the 2023 Beijing JOINN Biologics Leasing Agreements from 1 September 2023 (being the date when entered into the 2023 Beijing JOINN Biologics Leasing Agreements) to 30 August 2024 (being the date of the Announcement) was RMB971,510.39. As disclosed in the Announcement, the Group recognised the rental payments paid by the Group under the 2023 Beijing JOINN Biologics Leasing Agreements as acquisition of right-of-use asset in its consolidated statement of financial position, and the value of right-of-use asset under the 2023 Beijing JOINN Biologics Leasing Agreements are RMB14,522,000.

The transaction amount under the 2024 BioAI Software Service Framework Agreement was nil from 5 February 2024 (being the date of the 2024 BioAI Software Service Framework Agreement) to 30 August 2024 (being the date of the Announcement).

Information of BioAI and Yizhao (Beijing) Pharmaceutical Technology

The remaining approximately 18.43% shares of BioAI is ultimately owned as to: (a) approximately 9.54% reserved for the employee share option plan of BioAI; (b) approximately 0.2% by Ms. Feng Yujing (馮宇靜), a relative of Ms. Feng; and (c) approximately 8.69% by eight individuals, which are all independent third parties with each of them holding less than 5% shareholding in BioAI.

The remaining 15% shares of Yizhao (Beijing) Pharmaceutical Technology is owned as to 5% by each of Mr. Zuo Conglin (左從林), an executive Director, Mr. Zhang Hongshan (張洪山) and Ms. Li Tao (李濤), respectively.

Save as disclosed in this announcement, all information in the Announcement remains unchanged.

By order of the Board
JOINN Laboratories (China) Co., Ltd.
Feng Yuxia
Chairperson

Beijing, the PRC, 12 September 2024

As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng, Ms. Sun Yunxia and Dr. Yao Dalin as executive Directors, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.